Mancini Anthony sold $481K of RVMD
Mancini Anthony (See Remarks) sold 3,121 shares of Revolution Medicines, Inc. (RVMD) at an average of $153.99 ($153.30–$154.82, $0.48M total) across 3 trades on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the reported sale details (shares, price range, total value) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but there is no accompanying company-specific catalyst in the text.
What to watch
The filing does not state motives beyond the 10b5-1 plan, and the sale size ($480.6K) may be consistent with diversification or liquidity needs rather than negative fundamentals.
Background
This is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc.
Ticker impact
Form 4 shows officer Mancini Anthony sold 3,121 shares of Revolution Medicines at about $153.99 weighted average under a 10b5-1 plan.
Low near-term impact; any effect is likely sentiment-only and outweighed by broader biotech fundamentals.
The disclosure is a scheduled open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or regulatory news in the filing text.
Market effects
Minimal; single-company insider sale without new clinical, regulatory, or financing details does not reset sector expectations.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can reflect private caution; traders may still use it as a weak bearish sentiment input.
Key entities
- issuerRevolution Medicines, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderMancini Anthony
Officer who sold 3,121 shares in open-market transactions under a 10b5-1 plan.
